Skip to main content

Megan N. Gates

Member / Co-chair, Securities & Capital Markets Practice

[email protected]

+1.617.348.4443

Follow:
Share:

Megan is a prominent corporate and securities attorney who deftly steers public companies through capital-raising transactions, SEC reporting obligations, and mergers and acquisitions. She applies knowledge she gained during an earlier in-house role with a laboratory and analytical instrument maker to ably advise life sciences and other clients on corporate governance and SEC compliance matters.

Megan is a member of the Firm's Policy Committee and Co-chair of the Securities & Capital Markets Practice Group. She concentrates her practice on providing counsel to public companies with respect to public and private equity financings, merger and acquisition transactions, and compliance and disclosure obligations under the Securities Exchange Act of 1934.

Megan frequently advises clients on corporate governance matters, including compliance with the Sarbanes-Oxley Act of 2002. She also has extensive experience with tender offers, exchange offers, and going-private transactions.

Megan frequently speaks at conferences on securities offerings, corporate governance, and compliance matters, including at Massachusetts Continuing Legal Education (MCLE) panels and industry meetings.

Before joining the firm, Megan served as associate general counsel for Thermo Electron Corporation, where she was responsible for securities offerings and compliance for the corporation and its 23 publicly traded subsidiaries.

Education

  • Boston College (JD)
  • Wellesley College (BA)

Experience

Merger & Acquisition Transactions

  • Represented ChyronHego Corporation in its $120 million acquisition by Vector Capital Partners
  • Represented Chyron Corporation in its acquisition of Hego Aktiebolag
  • Represented Caliper Life Sciences, Inc. in its $600 million acquisition by PerkinElmer Corporation
  • Represented Coley Pharmaceutical Group, Inc. in its $164 million acquisition by Pfizer Inc.
  • Represented Targacept, Inc. in its merger with Catalyst Biosciences, Inc.
  • Represented RegenMedTX, LLC in its acquisition by a private equity firm
  • Represented EPIRUS Biopharmaceuticals, Inc. in its acquisition of Bioceros Holding B.V.

Securities Offerings

  • Represented Bank of America – Merrill Lynch in a $138 million follow-on offering by Puma Biotechnology, Inc.
  • Represented OvaScience, Inc. in a $50 million follow-on offering
  • Represented OXiGENE, Inc. in multiple follow-on offerings
  • Represented MELA Sciences, Inc. in a $10 million follow-on offering
  • Represented NeuroMetrix, Inc. in multiple follow-on offerings
  • Represented Coley Pharmaceutical Group in its $102.6 million initial public offering
  • Represented Targacept, Inc. in its $40.7 million initial public offering
  • Represent H.C. Wainwright & Co., LLC in multiple follow-on offerings by biotechnology issuers

Recognition & Awards

  • Casa Myrna: Recipient of Norman Knight Charitable Foundation Award (2014)
  • Women’s Business Boston: Top 10 Corporate Lawyers (2010)
  • Massachusetts Lawyers Weekly: Top Women of Law (2010)
  • Phi Beta Kappa

Involvement

  • Member, Boston Bar Association Council
  • Corporate Board Committee, The Boston Club
  • Life Sciences Council, Springboard Enterprises
  • Board of Directors, Wellesley College Business Leadership Council
  • Board of Directors, Greater Boston Legal Services
  • Curriculum Committee, Massachusetts Continuing Legal Education (MCLE)
  • Board of Directors, Pine Street Inn, a nonprofit organization that is New England’s largest resource for homeless men and women
  • Co-chair, Boston Bar Foundation John & Abigail Adams Benefit (2016)
  • Past Chair, Board of Directors, Casa Myrna, a nonprofit organization located in Boston that is working to end domestic violence in the lives of women and children
  • Past Co-chair, Boston Bar Association Business Transactions Section and Securities Law Committee

Languages

- Japanese

Recent Insights

News & Press

Viewpoints

The SEC has voted to amend the definition of the term “smaller reporting company” as used in its rules and regulations. In its adopting release for these changes, the SEC indicates that the amendments “…are intended to reduce compliance costs for registrants and promote capital formation, while maintaining appropriate investor protections.”
​​​​​​​
As our clients and friends know, each year Mintz Levin provides an analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission (the “SEC”) and their annual shareholder meetings.
The U.S. IPO market began 2017 with a solid start, with 25 IPOs raising nearly $10 billion in the first quarter and another 31 IPOs in the second quarter through May 15.
As our clients and friends know, each year Mintz Levin provides an analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission (the “SEC”) and their annual shareholder meetings.
The Securities and Exchange Commission (SEC) recently issued proposed amendments to increase the financial thresholds in the definition of a “smaller reporting company” that, if adopted, will increase the number of issuers that qualify as smaller reporting companies and thereby would benefit from the scaled disclosure requirements.
As our clients and friends know, each year Mintz Levin provides an analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission (the “SEC”) and their annual shareholder meetings.
As our clients and friends know, each year Mintz Levin provides an analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission (the “SEC”) and their annual shareholder meetings.
As our clients and friends know, each year Mintz Levin provides an analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission (the “SEC”) and their annual shareholder meetings.
A recent federal appeals court decision addressing pleading standards for shareholder suits under Section 11 of the Securities Act of 1933, as amended, highlights the potential dangers of giving broad assurances of legal compliance in registration statements.
As our clients and friends know, each year Mintz Levin provides an analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission (SEC) and their annual shareholder meetings.

News & Press

Mintz Member and Co-chair of the firm’s Securities & Capital Markets Practice Megan Gates is among the featured panelists at the 2017 Association of Corporate Counsel Annual Meeting.
Mintz represented G1 Therapeutics, Inc. in its initial public offering of 7,781,564 shares of common stock. G1 Therapeutics is a clinical-stage biopharmaceutical company.
Megan Gates, a Member and Co-chair of the Securities & Capital Markets Practice, is quoted in an Agenda article covering the SEC fining an audit firm for unprofessional conduct resulting from personal relationships.  
Daniel DeWolf, Co-Chair, Venture Capital and Emerging Companies, and Megan Gates, Co-chair of the Securities & Capital Markets Practice Group, authored this VC Experts Blog piece discussing how the world of raising capital has been evolving over the last several years.

Events

Moderator
Jan
14
2019

14th Annual Directors Forum

Global risk factors: preparing for the unpredictable

San Diego, CA

Speaker
Jun
12
2018

Director Education Forum 2018

American College of Corporate Directors

Dedham, MA

Speaker
May
22
2018

Basics for Directors,Understanding Board Mandatory Filings

American College of Corporate Directors

Webinar

Panelist
Jun
7
2017

2017 Public Markets Overview

Broadview Ventures, Inc.

Boston, MA

Speaker
Jun
15
2016

Director Education Forum 2016

American College of Corporate Directors

Dedham, MA

Speaker
Feb
11
2016

A Day in the Life of a Board Executive: Legal Responsibilities and Fiduciary Duties

Boston Women in Finance

Two Financial Center, Boston, MA

Speaker
Jun
10
2015

Director Education Forum 2015

American College of Corporate Directors Boston Forum

Speaker
Feb
11
2015

Public Company Director 101

Corporate Directors Group

Webinar